Understand diabetes research—without reading every study
| Intervention | Outcome | Strength |
|---|---|---|
| Dapagliflozin | HbA1c | Emerging |
| Lifestyle intervention for prediabetes | Body weight | Emerging |
| Digital physician-pharmacist collaborative care | HbA1c | Emerging |
Deep dives into key evidence areas with comprehensive research synthesis
Evidence related to lowering or improving HbA1c/A1C in diabetes management.
Evidence related to body weight reduction, BMI improvement, waist circumference, and body composition changes.
Evidence related to blood glucose control, fasting glucose, postprandial glucose, glucose variability, and time in range.
Evidence related to improving insulin resistance, insulin sensitivity, fasting insulin, C-peptide levels, and beta-cell function in diabetes and prediabetes.
Evidence related to preventing or delaying type 2 diabetes, reducing diabetes incidence, and improving metabolic risk in people with prediabetes.
Evidence related to diabetic kidney disease, albuminuria, kidney function, nephropathy progression, end-stage renal disease, and kidney-protective diabetes treatments.
Every study contributes evidence linking interventions and outcomes. deDiabetes organizes those findings into connected evidence topics so you can move from broad questions to supporting research.
Strongest findings from our evidence intelligence analysis
Metformin shows moderate improvement in HbA1c with consistent results (emerging research, 4 studies).
Emerging evidence suggests further research needed.
Dapagliflozin shows moderate improvement in HbA1c with consistent results (emerging research, 4 studies).
Emerging evidence suggests further research needed.
Semaglutide shows strong improvement in Body weight with consistent results (emerging research, 2 studies).
Moderate evidence warrants consideration with clinical context.
Insulin degludec shows strong improvement in Blood glucose with consistent results (emerging research, 2 studies).
Emerging evidence suggests further research needed.
Low-carbohydrate diet shows strong improvement in Body weight with consistent results (emerging research, 2 studies).
Emerging evidence suggests further research needed.
Low-carbohydrate diet shows strong improvement in HbA1c with consistent results (emerging research, 2 studies).
Emerging evidence suggests further research needed.
High-value evidence organized by strength, consistency, and research focus
Highest-ranked evidence pairs currently in database
Evidence with agreement across multiple studies
Interventions with the broadest evidence base
Promising early-stage research areas
Recently published research
Recently added studies and evidence pairs
Highest-ranked intervention and outcome relationships from the evidence graph
Ranked using evidence strength, validation, consistency, and study depth
| # | Intervention | Outcome | Effectiveness | Evidence Strength | Studies |
|---|---|---|---|---|---|
| 1 | Dapagliflozin | HbA1c | moderate_positive | Emerging | 0 |
| 2 | Lifestyle intervention for prediabetes | Body weight | moderate_positive | Emerging | 0 |
| 3 | Digital physician-pharmacist collaborative care | HbA1c | strong_positive | Emerging | 0 |
| 4 | Dapagliflozin | Time in range | strong_positive | Emerging | 0 |
| 5 | Complex lifestyle intervention | HbA1c | strong_positive | Emerging | 0 |
| 6 | Complex lifestyle intervention | Fasting blood sugar (FBS) | strong_positive | Emerging | 0 |
| 7 | Lifestyle intervention for prediabetes | Fasting blood sugar (FBS) | weak_positive | Emerging | 0 |
| 8 | Lifestyle intervention for prediabetes | HbA1c | moderate_positive | Emerging | 0 |
| 9 | Dapagliflozin | Body weight | weak_positive | Emerging | 0 |
| 10 | Resistance training | Fasting blood sugar (FBS) | weak_positive | Limited | 0 |
| 11 | Vitamin D supplementation | HbA1c | neutral | Limited | 0 |
| 12 | Dapagliflozin | Fasting blood sugar (FBS) | neutral | Limited | 0 |
How to Read Evidence Cards
Cards combine study count, effectiveness, consistency, and evidence strength into a quick research intelligence snapshot.
Strong evidence supports metformin as first-line therapy for improving blood sugar control in type 2 diabetes.
Backed by decades of research and consistent findings across diverse populations.
Overall confidence based on study quality, consistency, and depth
Observed direction and magnitude of outcomes
Whether multiple studies agree
Number of supporting research studies
Quick visual confidence indicator
Evidence scores are generated from aggregated research analysis and are not medical advice.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
